Skip to main content

Table 3 Comparing baseline and end of treatment data in Gp1 (N = 58)

From: Assessment of efficacy and safety of two Egyptian protocols for treatment-experienced HCV patients: an observational study

Parameter

Baseline

Week 12

P-value

ALT (IU/L)

33.5 (6.3–136.0)

17.0 (4.0–55.0)

< 0.001

AST (IU/L)

37.0 (7.0–139.0)

22.5 (10.0–60.0)

< 0.001

Albumin (g/dL)

4.2 (2.8–5.1)

4.0 (2.7–5.0)

0.628

Total bilirubin (mg/dL)

0.8 (0.3–4.5)

0.9 (0.3–3.0)

0.008

WBCs (109/L)

5.5 (2.5–13.7)

5.9 (2.5–17.0)

0.940

HB (%)

13.6 (8.0–16.7)

12.6 (5.9–15.2)

< 0.001

Creatinine (mg/dl)

0.8 (0.5–1.2)

0.9 (0.5–1.3)

0.008

Platelet (109/L)

192.5 (97.0–467.0)

203.0 (100–453.0)

0.918

  1. Values are presented median (range)
  2. ALT alanine aminotransferase, AST aspartate aminotransferase, WBCs white blood cells, HB hemoglobin, P value ≤ 0.05 is considered significant
  3. Gp1 received sofosbuvir 400 mg/day plus daclatasvir 60 mg/day plus simeprevir 150 mg/day plus ribavirin 15 mg/kg/day for 12 weeks